MSI2 and chronic myelogenous leukemia, BCR-ABL1 positive: Recently, MSI2 dysregulation has been reported in various hematology and solid tumors, including acute and chronic myeloid leukemia (AML and CML), brain, lung, gastric, hepatocellular and bladder cancers [10–15].